Results 1 to 10 of about 72,428 (200)

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis

Journal of Experimental & Clinical Cancer Research, 2023
Background Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. The present study aimed to explore
Yan Li, Wenjuan Yang, Yuanyuan Zheng, Weiqi Dai, Jie Ji, Liwei Wu, Ziqi Cheng, Jie Zhang, Jingjing Li, Xuanfu Xu, Jianye Wu, Mingwei Yang, Jiao Feng, Chuanyong Guo   +13 more
doaj   +2 more sources

Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research, 2022
Background Macropinocytosis, an important nutrient-scavenging pathway in certain cancer cells, allows cells to compensate for intracellular amino acid deficiency under nutrient-poor conditions.
Jun-Kyu Byun, Seunghyeong Lee, Gil Won Kang, Yu Rim Lee, Soo Young Park, Im-Sook Song, Jae Won Yun, Jaebon Lee, Yeon-Kyung Choi, Keun-Gyu Park   +9 more
doaj   +2 more sources

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase

Cell Death and Disease, 2023
Sorafenib, a first-line drug for advanced hepatocellular carcinoma (HCC), shows a favorable anti-tumor effect while resistance is a barrier impeding patients from benefiting from it. Thus, more efforts are needed to lift this restriction.
Feng-li Xu, Xiao-hong Wu, Chang Chen, Kai Wang, Lu-yi Huang, Jie Xia, Yi Liu, Xue-feng Shan, Ni Tang   +8 more
doaj   +2 more sources

Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance

Cells, 2022
Sorafenib is a small molecule that blocks tumor proliferation by targeting the activity of multi-kinases for the treatment of advanced hepatocellular carcinoma (HCC). Increasing sorafenib resistance following long-term treatment is frequently encountered.
Yung-Sheng Chang, Chien-Wei Su, San-Chi Chen, Yen-Ying Chen, Yuh-Jin Liang, Jaw-Ching Wu   +5 more
doaj   +1 more source

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

JAMA Oncology, 2023
Key Points Question How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings In this phase 3 randomized clinical trial of 674
Shukui Qin, M. Kudo, Tim Meyer, Y. Bai, Yabing Guo, Zhiqiang Meng, T. Satoh, D. Marino, E. Assenat, Songzi Li, Yaxi Chen, F. Boisserie, R. Abdrashitov, R. Finn, Arndt Vogel, Andrew X. Zhu   +15 more
semanticscholar   +1 more source

Anterior gradient 2 induces resistance to sorafenib via endoplasmic reticulum stress regulation in hepatocellular carcinoma

Cancer Cell International, 2023
Background Hepatocellular carcinoma (HCC) accounts for almost 80% of all liver cancer cases and is the sixth most common cancer and the second most common cause of cancer-related death worldwide.
Hung-Wen Tsai, Yi-Li Chen, Chun-I Wang, Ching‑Chuan Hsieh, Yang-Hsiang Lin, Pei-Ming Chu, Yuh-Harn Wu, Yi-Ching Huang, Cheng-Yi Chen   +8 more
doaj   +1 more source

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib

Pharmaceutics, 2020
Prior studies have demonstrated an organic anion transporter 6 (OAT6)-mediated accumulation of sorafenib in keratinocytes. The OAT6 inhibitor probenecid decreases sorafenib uptake in skin and might, therefore, decrease sorafenib-induced cutaneous adverse
Koen G. A. M. Hussaarts, Leni van Doorn, Karel Eechoute, Jeffrey Damman, Qiang Fu, Nadia van Doorn, Eric D. Eisenmann, Alice A. Gibson, Esther Oomen-de Hoop, Peter de Bruijn, Sharyn D. Baker, Stijn L. W. Koolen, Teun van Gelder, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen, Alex Sparreboom, Sander Bins   +16 more
doaj   +1 more source

Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib

Cancer Communications, 2023
Cancer‐associated fibroblasts (CAFs) play an important role in the induction of chemo‐resistance. This study aimed to clarify the mechanism underlying CAF‐mediated resistance to two tyrosine kinase inhibitors (TKIs), sorafenib and lenvatinib, and to ...
J. Eun, J. H. Yoon, H. Ahn, Seokhwi Kim, Young Bae Kim, S. Lim, Won Park, Tae Wook Kang, G. Baek, M. Yoon, J. Son, Ji Hyang Weon, S. Kim, H. Cho, J. Cheong   +14 more
semanticscholar   +1 more source

Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells

Frontiers in Pharmacology, 2021
The multireceptor tyrosine kinase inhibitor sorafenib is a Food and Drug Administration-approved first-line drug for the treatment of advanced liver cancer that can reportedly extend overall survival in patients with advanced hepatocellular carcinoma ...
Wubin He, Xiaoxu Huang, Bradford K. Berges, Yue Wang, Ni An, Rongjian Su, Yanyan Lu   +6 more
doaj   +1 more source

Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de‐palmitoylation

Clinical and Translational Medicine, 2023
Background Ferroptosis is an important iron‐dependent form of cell death in hepatocellular carcinoma (HCC). Sorafenib, a potent ferroptosis inducer, is used to treat advanced HCC but its efficacy is limited by the development of drug resistance.
Zhehao Shi, Zhiming Li, Bin Jin, W. Ye, Luhui Wang, Sina Zhang, Jiuyi Zheng, Zixia Lin, Bo Chen, Fangting Liu, Baofu Zhang, X. Ding, Zhen Yang, Y. Shan, Zhengping Yu, Yi Wang, Ji-Cai Chen, Qiang Chen, L. Roberts, Gang Chen   +19 more
semanticscholar   +1 more source